The aim of the study is to evaluate the feasibility defined as overall tolerance and toxicity as well as relative dose-intensity and cumulative dose delivered, of an association ofgemcitabine, oxaliplatin and radiotherapy in patients with locally advanced and unresectable, but non-metastatic pancreatic adenocarcinoma or cholangiocarcinoma

Inclusion Criteria:

• Histologically proven and unresectable adenocarcinoma of the pancreas or cholangiocarcinoma with no evidence of metastatic disease
• WHO performance status of 0 or 1
• Complete recovrey from surgery in case an enteric and/or biliary tract by-pass operation has been performed
• Maximum delay after surgery: 8 weeks
• No previous or co-existent malignant disease except non melanoma skin cancers and adequately treated cervic carcinoma in situ
• Adequate bon marrow reserve
• No previous chemotherapy or radiotherapy
• Expected survival > 6 months

Exclusion Criteria:

• Active infection
• Metastatic disease
• Inadequate liver function after derivative surgery
• Inadequate renal function
• Pregnancy, breast feeding
• Use of any other investigational agent in the month before enrollment
• Patients with grade 2 or more neuropathy